20 August 2021 – Allscripts has won a competitive tender to deliver an electronic chemotherapy prescribing solution to SA Health. The solution, which will be integrated with SA Health’s Sunrise EMR, will be rolled out to more than 20 hospitals and facilities across SA Health sites that offer cancer treatment services across South Australia.

The solution being implemented by Allscripts is the cloud-based iQemo solution by UK company iQHealthTech. iQemo is a specialist platform which provides a complete end-to-end chemotherapy prescribing solution that includes predefined regimens, prescribing, scheduling, dispensing, through to chemotherapy administration and reporting.

iQemo was designed and perfected with practicing oncologists and is used by several NHS Trusts and private healthcare groups in the UK, including those where Allscripts SunriseTM is the EMR platform of choice. SA Health will be able to access iQemo within Sunrise EMR enabling a more complete patient record.

SA Health partners with Allscripts Australia to deliver its state-based Sunrise EMR and PAS. Sunrise is deployed in many of the state’s public hospitals and healthcare facilities including its flagship Royal Adelaide Hospital, Flinders Medical Centre, The Queen Elizabeth Hospital, Noarlunga Health Service, Mt Gambier and Districts Health Service and many others as part of a statewide rollout to create a connected community of health in the state of South Australia.

Todd Haebich, General Manager for Allscripts ANZ said that iQemo drastically reduces the risk of dosing errors and meets SA Health’s need for coordinated care of cancer patients.

“The combination of our relationship with iQHealthTech, and the power and capability of Microsoft Azure, allows us to deliver an exceptional SaaS product to SA Health that has been tried and tested in the UK and that enhances both efficiency and patient safety associated with the prescribing and administration of chemotherapy,” explained Mr. Haebich.

“It provides many features that improve patient safety such as comprehensive chemotherapy regimen management, automatic dose calculations, allergy & sensitivity alerting, decision support linked to pathology & toxicity, drug-to-drug interaction support and much more.”

SA Health ECPS Project Director, Paul Thomas, said that during the procurement process, suppliers had to demonstrate how they would deliver the desired clinical outcomes, with the evaluation led by the doctors, nurses and pharmacists who treat cancer patients and the technical teams who will be part of the planning and design stage.

“The Evaluation Team recognised the importance of a supplier with the right skill set in Australia when selecting a UK-based system,” he said.

“Local on-the-ground support is crucial to the implementation and working with clinical and technical experts in SA Health.”

“Allscripts has a detailed understanding of SA Health’s clinical, business and technical environment and will deliver the iQemo solution in partnership with iQemo experts working alongside them from the UK. This approach provides SA Health with the confidence that a safe and timely delivery of the iQemo solution will be achieved.”

iQemo reduces the risk of error by providing a clear, easy to read electronic drug administration chart with all the drugs displayed in the correct order based on the treatment protocol.

ENDS

About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of HealthTM. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.alterahealth.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

###

© 2021 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

For more information contact:

Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com